Alveo Technologies is developing diagnostics for early detection of illness and disease. As is seen with the SARS-Cov-2 pandemic, infectious diseases affect everyone, everywhere. Alveo is addressing this problem by providing rapid, reliable and economical cloud-based diagnostics. To achieve this, Alveo condenses all the current diagnostic methods into a single-step process known as the be.well platform. The steps include sample preparation, nucleic acid amplification and real-time detection in a single isothermal microfluidic channel. Alveo hopes to use this information to track global infectious diseases by having at-home diagnostic results. The company is currently developing the platform for Flu A/B, COVID-19 and RSV. 

<p>Alveo Technologies is developing diagnostics for early detection of illness and disease. As is seen with the SARS-Cov-2 pandemic, infectious diseases affect everyone, everywhere. Alveo is addressing this problem by providing rapid, reliable and economical cloud-based diagnostics. To achieve this, Alveo condenses all the current diagnostic methods into a single-step process known as the be.well platform. The steps include sample preparation, nucleic acid amplification and real-time detection in a single isothermal microfluidic channel. Alveo hopes to use this information to track global infectious diseases by having at-home diagnostic results. The company is currently developing the platform for Flu A/B, COVID-19 and RSV. </p>


Alveo Technologies

Founded: 2014
Location: Alameda, CA
Employee range: 11 - 50
Funding: $38M A Jan 2018

Short description:

Drug notes:

Long description:

Jobs: